Skip to main content

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

Clinical Trial Grant
Duke Scholars

Administered By

Dermatology

Awarded By

AbbVie Inc.

Start Date

March 13, 2024

End Date

March 12, 2027
 

Administered By

Dermatology

Awarded By

AbbVie Inc.

Start Date

March 13, 2024

End Date

March 12, 2027